{"url_path":"/sec/hae/8-k/2026-06-05/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-05","source_url":"https://www.sec.gov/Archives/edgar/data/313143/0000313143-26-000057-index.html","accession_number":"0000313143-26-000057","cik":"0000313143","ticker":"HAE","issuer_name":"HAEMONETICS CORP","edgar_url":"https://www.sec.gov/Archives/edgar/data/313143/0000313143-26-000057-index.html","primary_entity_key":"0000313143","primary_entity_name":"HAEMONETICS CORP"},"word_count":252,"has_tables":true,"body_markdown":"Item 7.01 Regulation FD Disclosure.\n\nOn June 5, 2026, Haemonetics Corporation (the \"Company\") issued a press release announcing changes to its reportable segment structure to better align external financial reporting with how the Company manages its business and allocates resources. Beginning with the first quarter of fiscal 2027, the previously reported Plasma and Blood Center segments will be combined into a single reportable segment, Apheresis, while the Hospital segment will be renamed MedSurg. The updated segment names more accurately reflect the underlying businesses, technologies, and markets served. In connection with this announcement, the Company has posted to the Investor Relations page on its website (www.haemonetics.com) a supplemental presentation outlining the reporting changes, including quarterly historical reconciliations from the first quarter of fiscal year 2024 through the fourth quarter of fiscal year 2026, and the company has provided a recast of its previously issued fiscal 2027 guidance in the new segment structure. The Company is not reaffirming or updating its previously issued fiscal year 2027 guidance. Updates, if any, will be provided on the Company’s first quarter fiscal year 2027 earnings call.\n\nThe foregoing information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing."}